Prescribing of Low-Molecular-Weight Heparin and Warfarin in Patients with Acute Venous Thromboembolism and Active Cancer

Prescribing of Low-Molecular-Weight Heparin and Warfarin in Patients with Acute Venous Thromboembolism and Active Cancer

Background: Malignancy is a significant risk factor for venous thromboembolism (VTE), conferring a 4- to 7-fold increased risk in patients with cancer. Because of its effect on certain tumors, low-molecular-weight heparin (LMWH) has been evaluated as a treatment option for cancer and as an alternati...

Full description

Bibliographic Details
Main Authors: Steward, David W., Bossaer, John B., Odle, Brian, Flores, Emily, Rikhye, Somi
Published: Digital Commons @ East Tennessee State University 2014
Subjects:
patients
rural communities
pharmacological treatment
active cancer
acute VTE
heparin
warfarin
Pharmacy Practice
Oncology
Pharmacy and Pharmaceutical Sciences
Online Access:https://dc.etsu.edu/etsu-works/2322
http://jhoponline.com/jhop-issue-archive/2014-issues/december-vol-4-no-4/16295-prescribing-of-low-molecular-weight-heparin-and-warfarin-in-patients-with-acute-venous-thromboembolism-and-active-cancer

Internet

https://dc.etsu.edu/etsu-works/2322
http://jhoponline.com/jhop-issue-archive/2014-issues/december-vol-4-no-4/16295-prescribing-of-low-molecular-weight-heparin-and-warfarin-in-patients-with-acute-venous-thromboembolism-and-active-cancer

Similar Items